China's National Medical Products Administration has accepeted Jiangsu Hengrui Medicine's (SHA:600276) drug marketing authorization application for its Ruilafupu-α injection, according to a Thursday disclosure on the Shanghai Stock Exchange.
The pharmaceutical company invested 587.9 million yuan into the research and development of the drug, which is used to treat locally advanced unresectable, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma.
Shares of the company dropped less than 5% in recent trade.
Price (RMB): ¥42.68, Change: ¥-2.3, Percent Change: -5.16%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments